Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.

Current drug metabolism - 1 May 2008

Ribelles N, López-Siles J, Sánchez A, González E, Sánchez M J, Carabantes F, Sánchez-Rovira P, Márquez A, Dueñas R, Sevilla I, Alba E

Abstract excerpt

Capecitabine is a drug that requires the consecutive action of three enzymes: carboxylesterase 2 (CES 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP) for transformation into 5-fluorouracil (5FU). The metabolism of 5FU requires the activity of thymidylate synthase (TS) and dihydropy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Capecitabine
Share to Carboxylesterase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Dihydrouracil Dehydrogenase (NADP)

Share to Fluorouracil

Share to Pilot Projects

Share to Thymidylate Synthase

Source

Identifiers

PMID: 18473752
DOI: 10.2174/138920008784220646

Genes

CES2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18473752-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.PMID 18473752Read ↗

A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.Semantic proximity Read ↗

The role of pharmacogenetics in capecitabine efficacy and toxicity.Semantic proximity Read ↗

Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer.Semantic proximity Read ↗

Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity.Semantic proximity Read ↗

Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYDSemantic proximity Read ↗

[Translated article] Genetic variants and enzyme activity in citidin deaminase: Relationship with capecitabine toxicity and recommendation for dose adjustment.Semantic proximity Read ↗

Genetic variants and enzyme activity in citidin deaminase: Relationship with capecitabine toxicity and recommendation for dose adjustment.Semantic proximity Read ↗

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.Semantic proximity Read ↗

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.Semantic proximity Read ↗

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.Semantic proximity Read ↗

Pharmacogenomics of fluorouracil -based chemotherapy toxicity.Semantic proximity Read ↗

Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.